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BACKGROUND: Identification of endometrial carcinoma (EC) patients at high risk of recurrence is lacking. In this study, the
prognostic role of hypoxia and angiogenesis was investigated in EC patients.
METHODS: Tumour slides from EC patients were stained by immunofluorescence for carbonic anhydrase IX (CAIX) as hypoxic
marker and CD34 for assessment of microvessel density (MVD). CAIX expression was determined in epithelial tumour cells, with a
cut-off of 1%. MVD was assessed according to the Weidner method. Correlations with disease-specific survival (DSS), disease-free
survival (DFS) and distant disease-free survival (DDFS) were calculated using Kaplan–Meier curves and Cox regression analysis.
RESULTS: Sixty-three (16.4%) of 385 ECs showed positive CAIX expression with high vascular density. These ECs had a reduced DSS
compared to tumours with either hypoxia or high vascular density (log-rank p= 0.002). Multivariable analysis showed that hypoxic
tumours with high vascular density had a reduced DSS (hazard ratio [HR] 3.71, p= 0.002), DDFS (HR 2.68, p= 0.009) and a trend for
reduced DFS (HR 1.87, p= 0.054).
CONCLUSIONS: This study has shown that adverse outcome in hypoxic ECs is seen in the presence of high vascular density,
suggesting an important role of angiogenesis in the metastatic process of hypoxic EC. Differential adjuvant treatment might be
indicated for these patients.
British Journal of Cancer (2019) 120:1037–1044; https://doi.org/10.1038/s41416-019-0461-2
BACKGROUND
Most endometrial carcinoma (EC) patients present with early-stage
disease and have a favourable outcome. Nevertheless, 15% of all
patients suffer from recurrent disease and subsequently have a
poor outcome.1–3 Approximately half of these recurrences occur in
patients primarily diagnosed with low-risk EC.1,4 Improved
identification of patients at high risk for recurrence is crucial to
prevent both over- and undertreatment.
Hypoxia is known to be an important feature of aggressive EC
and drives metastatic potential.5–8 When solid tumours outgrow
their vasculature beyond the size of 0.1 mm3, hypoxia may occur.9
As a response to chronic hypoxia, tumour cells will activate genes
associated with more aggressive phenotype and resistance to
chemotherapy and radiotherapy.10 Hypoxia-inducible factor 1
(HIF-1), formed after heterodimerisation of its subunits HIF-1α and
HIF-1β, plays a key role in this process.11,12 HIF-1 activates
downstream genes that enhance cell survival by maintaining
intracellular pH, stimulating angiogenesis to increase oxygen
delivery and switching to anaerobic glycolysis.12,13 More specifi-
cally, an important downstream target is carbonic anhydrase 9
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(CA9), whose encoded protein, carbonic anhydrase IX (CAIX),
regulates intracellular pH by converting carbon dioxide to
carbonic acid.14 By adaptation of tumour cells to a hostile
microenvironment, tumour proliferation can commence even in
hypoxic areas.15 Also in normoxic conditions, HIF-1 can be
activated; however, downstream activation is present in lesser
extent.16,17 In this perspective CAIX expression, one of the key
effector proteins of HIF-1, has been shown to be more specifically
related to hypoxia and poor outcome.18
Next to maintenance of intracellular pH, stimulation of
angiogenesis is an important response to hypoxia. Vascular
endothelial growth factor (VEGF), another downstream target of
HIF-1, is also correlated with hypoxia and angiogenesis in several
cancer types, including EC.19–22 Angiogenesis can be assessed by
microvessel density (MVD) and is prognostically associated with
deep myometrial invasion (MI), lymphovascular space invasion
(LVSI) and poor overall survival in EC.23 Although earlier studies
suggest correlation between hypoxia, angiogenesis and poor
outcome, the prognostic value has not yet been studied before.5,6
Therefore, we have investigated the prognostic value of hypoxia
and angiogenesis in EC, assessed with CAIX expression and MVD.
METHODS
Patients
Data and tumour slides were collected previously for a study
analysing the value of L1CAM expression in ECs, which included
ECs from 11 collaborating European Network for Individualised
Treatment of Endometrial Cancer (ENITEC) centres.24,25 Only cases
diagnosed by an expert gynaecological pathologist, with com-
plete data on treatment and pathological examination and at least
36 months of follow-up, were included. Cases with a non-
endometrioid component were categorised as non-endometrioid.
The 1199 cases included in the original study were randomly
selected using SPSS version 22 (SPSS IBM, New York, NY, USA),
resulting in a database of 403 patients for the present study. These
cases were not statistically different from the original cases for the
most important baseline characteristics.
Tissue and staining
Four micrometre sections, derived from formalin-fixed, paraffin-
embedded ECs were used to visualise CAIX and blood vessels.
Sections were mounted on Superfrost slides (Menzel–Gläser).
Slides were deparaffinated in Histochoise (VWR H103-4L) and
rehydrated (graded ethanol: 100–96–70% and de-ionised water).
Next, citrate buffer antigen retrieval was performed for 30 min
(Target retrieval solution 10×, pH 6 citrate, Dako Cytomation,
96 °C). Prior to incubation with the primary antibodies, sections
were blocked with 5% normal goat serum (Jackson ImmunoR-
esearch) in primary antibody diluent (PAD, BIORAD BUF014), 30
min at room temperature. Thereafter, sections were co-stained for
CAIX (Novus Biologicals NB100-417, 1:100) and vessels (CD34,
ABCAM ab8536, 1:300), 60 min at 37 °C. Secondary incubation was
performed using CyTM3 Fab Fragment Goat Anti-Rabbit immu-
noglobulin G (IgG) (H+ L) polyclonal IgG (Jackson ImmunoRe-
search 111-167-003) for CAIX and CF®488a Goat anti-Mouse IgG (H
+ L), F(ab′)2 fragment polyclonal IgG (Biotium CF488A) for the
vessels, 60 min at 37 °C. All antibodies were diluted in PAD. In
between stainings, sections were rinsed with phosphate-buffered
saline (JT Baker 4391.9010). 4′,6-Diamidino-2-phenylindole (DAPI)
(Santa Cruz Biotechnology AB-17.0097) was used as a counterstain
to stain all nuclei, and finally the sections were mounted with
Fluoromount W (Serva 21634.01). Haematoxylin and eosin staining
was used for morphological evaluation. CAIX expression was
scored as the fraction of epithelial tumour cells with positive
membranous staining.
Image analysis
Tumour slides were analysed using a digital image analysis system
after scanning of the whole slides with the Axio Imager D2
microscope (Carl Zeiss, GmbH, Oberkochen, Germany) using a
Prior lumen 200 metal halide lamp (Prior Scientific, Rockland, USA),
Axiocam 503 mono 16-bit camera (1936 × 1460 pixel, Carl Zeiss,
GmbH) and a computer-controlled motorised stage (Carl Zeiss,
GmbH) directed by Zen Pro software (Carl Zeiss, GmbH).26 Each
slide was scanned for three signals: DAPI (all nuclei), Alexa488
(CD34) and Cy3 (CAIX), by means of a 10× objective using
standardised shutter times for each signal (1, 25 and 50ms,
respectively). After scanning, grey-scale images of all three
recorded signals were used for analysis.
For analysis of CAIX staining, only membranous expression on
epithelial tumour cells was analysed. Areas of necrosis, large
vessels and tumour stroma, determined using H&E-stained
adjacent tumour slides, were therefore manually excluded from
the analysis (i-Vision for Mac; BioVision Technologies, Exton, PA,
USA). Next, thresholds for segmentation of the fluorescent
signals were interactively set above the background staining for
each individual marker and adjusted for each sample in order to
optimise the signal to background ratio using ImageJ software
(Wayne Rasband, National Institute of Mental Health, National
Institutes of Health). An interactively set threshold limits inter-
sample variability by correction for differences in immunofluor-
escence staining intensity.26,27 The resulting binary images were
used to calculate the fraction of CAIX (fCAIX) relative to the total
tumour area. To minimise bias of non-specific staining, only
positive signals exceeding 5 pixels were included.
The MVD was measured according to the Weidner method.28
In short, surrounding epithelial tumour cells three areas with
the highest density of vessels were selected by the assessor
(M.A.) using a ×200 magnification. To correct for objects that
exceed the image borders, only objects exceeding the left
and upper border were included. To minimise bias of non-
specific staining, only positive signals exceeding 2 pixels were
included.
CAIX expression was considered positive when the fCAIX was
above 1%.29,30 The MVD was dichotomised over the median. A
representative example of CAIX and MVD staining is shown in
Fig. 1.
Statistical analyses
Clinicopathological differences between subgroups were com-
pared with the χ2 and Fisher’s exact tests for categorical data and
the Mann–Whitney U test for continuous variables.
Kaplan–Meier curves were constructed for disease-specific
survival (DSS), disease-free survival (DFS) and distant-DFS (DDFS).
The association between CAIX and MVD and DSS, DFS and DDFS
was determined using Cox regression analysis. DSS was calculated
from the date of primary treatment to the date of death caused by
the disease or, for surviving patients, to the date of the last follow-
up. DFS and DDFS were defined as the length of follow-up, after
completion of the primary treatment, during which women
survived without any clinical sign of (distant) disease recurrence.
Distant recurrence included metastases in distant organs and
para-aortic lymph nodes. Features identified by univariable
regression analysis with p < 0.20 were used for multivariable
regression analysis. LVSI was coded as negative in case of missing
data (n= 108) since only substantial LVSI was recently reported as
relevant for prognosis of EC. If LVSI was not reported in the
pathological report, it was therefore assumed that LVSI was
absent.31,32 P values <0.05 were considered to indicate a
significant difference. SPSS version 25 (SPSS IBM, New York, NY,
USA) statistical software was used to perform the statistical
analyses.
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Fig. 1 Example of carbonic anhydrase IX (CAIX) and CD34 staining in endometrial cancer. a Nuclear 4′,6-diamidino-2-phenylindole (DAPI)
staining (blue) for visualisation of tumour nuclei. b CAIX staining (green) adjusted for total tumour area, meaning that only epithelial tumour
cells were included in the analysis: other tissue, including stroma, necrosis and vasculature has manually been removed and is coloured black
by the analysis software (see “Methods” section). c CD34 staining of vasculature (red) with three hotspots according to the Weidner method,
marked with the interrupted lines. d Combined CAIX staining and CD34 staining. e–h represent representative high-magnification images of
the boxed areas in a, b, c and d, respectively. Scale bar= 0.5 mm
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After staining for CAIX and CD34, 18 of the 403 patients were
excluded due to insufficient tumour tissue (n= 9) and excess of non-
specific background staining (n= 9). Clinicopathological character-
istics of the 385 patients included for analysis are shown in Table 1.
Overall, the median age was 64 years and the median follow-up time
was 58 months. Of all patients alive at the end of follow-up, 99% had
a follow-up of at least 36 months. A total of 67 patients (17.4%) were
diagnosed with high-grade EC, including 13 non-endometrioid
endometrial carcinomas (NEECs) (3.4%). In total, 106 (27%) EC
patients had positive CAIX expression. Forty-seven patients (12.2%)
recurred and 21 patients (5.5%) died due to the disease. Of all the
patients with recurrence, 14 (3.6%) had a local recurrence, 16 (4.2%)
a regional recurrence and 31 (8.1%) a distant recurrence.
CAIX expression and MVD
A total of 63 carcinomas (16.4%) showed a positive membranous
epithelial CAIX expression and high degrees of vascular density,
defined as a MVD above the median (Table 1). CAIX expression
with high vascular density was correlated with non-endometrioid
histology (7.9% vs. 2.5%, p= 0.028), but not with other
clinicopathological features. Patients with CAIX-positive ECs and
high vascular density experienced more recurrences (22.2% vs.
10.2%, p= 0.008) and specifically more distant recurrences (19.0%
vs. 5.9%, p < 0.001), as well as higher overall mortality (22.2% vs.
11.8%, p= 0.027) and EC-related mortality (17.5% vs. 3.7%, p <
0.001) (Table 1).
Figure 2 shows that CAIX expression with high vascular density
was associated with a worse DSS compared to CAIX expression
with low vascular density and negative CAIX expression (p=
Table 1. Baseline characteristics of all included patients, associated with CAIX combined with vascular density
Variable All (n= 385) Not CAIX >1% and high vascular density
(n= 322)
CAIX >1% and high vascular density
(n= 63)
P*
Age (years)a 64.0 (34.0–89.0) 64.3 (34.0–89.0) 63.5 (43.0–88.0) 0.634
Follow-up (months)a 65.1 (0.0–156.0) 63.8 (0.0–156.0) 71.6 (0–148.0) 0.125
Grade
Low 318 (82.6) 270 (83.9) 48 (76.2) 0.142
High 67 (17.4) 52 (16.1) 15 (23.8)
Histology
EEC 372 (96.6) 314 (97.5) 58 (92.1) 0.028
NEEC 13 (3.4) 8 (2.5) 5 (7.9)
FIGO stage
I–II 363 (93.8) 305 (94.7) 58 (92.1) 0.406
III–IV 22 (5.7) 17 (5.3) 5 (7.9)
Myometrial invasion
<50% 258 (67.2) 218 (67.9) 40 (63.5) 0.494
≥50% 126 (32.8) 103 (32.1) 23 (36.5)
LVSIb
No 243 (62.8) 200 (90.1) 43 (84.3) 0.234
Yes 30 (7.8) 22 (9.9) 8 (15.7)
Lymph nodesc
No metastasis 263 (68.0) 223 (95.7) 40 (95.2) 0.891
Metastasis 12 (3.1) 10 (4.3) 2 (4.8)
Adjuvant treatment
No 154 (40.0) 143 (44.8) 22 (34.9)
Radiotherapy 200 (51.9) 161 (50.0) 39 (61.9) 0.084
Chemotherapy 31 (8.1) 18 (5.6) 2 (3.2) 0.429
Recurrence
No 338 (87.8) 289 (89.8) 49 (77.8)
Yes 47 (12.2) 33 (10.2) 14 (22.2) 0.008
Local 14 (3.6) 12 (3.7) 2 (3.2) 0.830
Regional 16 (4.2) 13 (4.0) 3 (4.8) 0.792
Distant 31 (8.1) 19 (5.9) 12 (19.0) <0.001
Death
No 335 (87.0) 284 (88.2) 49 (77.8)
Yes 50 (13.0) 38 (11.8) 14 (22.2) 0.027
EC-related 21 (5.5) 12 (3.7) 11 (17.5) <0.001
CAIX carbonic anhydrase IX, EEC endometrioid endometrial carcinoma, NEEC non-endometrioid endometrial carcinoma, FIGO International Federation of
Gynaecology and Obstetrics, LVSI lymphovascular space invasion, EC endometrial carcinoma
*P value of the Mann–Whitney U test for continuous, and χ2 test and Fisher’s exact for categorical variables
aMedian values (range)
bBased on 273 patients
cBased on 275 patients
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0.002). Interestingly, CAIX-positive ECs with low vascular density
had a similar outcome as CAIX-negative ECs. Univariable Cox
regression analysis revealed that age, CAIX expression with high
vascular density, myocardial infarction (MI), International Federa-
tion of Gynaecology and Obstetrics (FIGO) stage, grade and
lymphovascular space invasion (LVSI) were significantly associated
with DSS (Fig. 3). In multivariable analysis, high age, CAIX
expression with high vascular density and tumour grade 3
remained significantly associated with reduced DSS, with CAIX
and MVD as the most significant parameter (hazard ratio [HR] 3.71,
95% confidence interval (CI) 1.59–8.63, p= 0.002).
Multivariable analysis showed that age, FIGO stage and LVSI
were significantly associated with DFS. CAIX expression with high
vascular density was nearly significant (HR 1.87, 95% CI 0.99–3.55,
p= 0.054, Fig. 4). Multivariable analysis for DDFS showed that LVSI
and CAIX expression with high vascular density was significantly
associated with a reduced DDFS (CAIX and MVD: HR 2.68, 95% CI
1.27–5.65, p= 0.009, Fig. 5).
Individual contribution of CAIX and MVD
Positive CAIX expression was associated with high tumour grade,
non-endometrioid histology, higher median MVD and treatment
with radiotherapy. In multivariable analysis, CAIX and grade were
significantly associated with DSS (HR 2.45, 95% CI 1.05–5.73, p=
0.039) (Supplementary Tables 1 and 2). High MVD was correlated
with deep MI, but not with other clinicopathological factors. In
multivariable analysis, high MVD remained an independent
predictor of reduced DSS (HR 2.92, 95% CI 1.13–7.54, p= 0.027)
(Supplementary Tables 3 and 4). Continuous scoring of CAIX
expression showed a significant correlation with DSS as well (data
not shown).
DISCUSSION
In the present study, we have investigated the prognostic value of
angiogenesis and hypoxia, assessed with MVD and CAIX expres-
sion. We hypothesised that angiogenesis would facilitate haema-
togenous spread of hypoxic tumour cells with subsequent poor
clinical outcome. Additionally, we assumed that this would
specifically be facilitated in hypoxic ECs, because of activation of
intracellular pathways that induce an aggressive and metastatic
phenotype. We have shown that CAIX expression with high
vascular density is associated with reduced DSS and DDFS.
Interestingly, CAIX-positive ECs with low vascular density had a
similar outcome as CAIX-negative ECs. Finally, multivariable
analyses for CAIX expression and vascular density showed that
both were independent prognostic markers as well.
This is the largest study to date studying CAIX in EC. In contrast
to previous studies in EC, we did find significant correlations
between CAIX expression and poor outcome, especially in case of
high vascular density. Seeber et al.29 included 93 patients and
found CAIX expression in 76% of ECs.29 In this study, no
correlation between CAIX expression and outcome was found;
however, small sample size and different cut-off value (all degrees
of positive staining were regarded as positive) could explain
why no correlation was found. Similarly, Pijnenborg et al.22
investigated CAIX expression in 59 ECs and did not find a
correlation. Again, possibly this study was underpowered due to a
limited sample size and low number of distant recurrences. Also,
differences in study design (case–control study) hamper valid
comparison with our results. In other cancer types, including
breast carcinoma, hepatocellular carcinoma, cervical carcinoma
and renal cell carcinoma, CAIX expression is associated with poor
prognosis.33–37 More specifically, increased distant failure was seen
in several solid tumour types with positive CAIX expression.37,38
The metastatic process is a complex step-wise process,
including acquisition of an aggressive phenotype, invasion in
surrounding tissues and blood vessels, survival in the circulation
with subsequent extravasation and colonisation in new organs.39
Hypoxia and subsequent neoangiogenesis will intervene with
Disease-specific survival
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Fig. 2 Disease-specific survival (DSS) by carbonic anhydrase IX
(CAIX) expression combined with degree of angiogenesis. Log-rank
test was used to compare groups
Disease-specific survival
3.74 (1.48–9.49) p= 0.005
2.78 (1.08–7.17) p= 0.034
p= 0.002
4.28 (1.88–9.76) p< 0.001
7.35 (2.86–18.88) p< 0.001
6.39 (2.81–14.53) p< 0.001
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Fig. 3 Univariable and multivariable Cox regression analysis of clinicopathological parameters including carbonic anhydrase IX (CAIX)
combined with vascular density for disease-specific survival (DSS). The hazard ratios with 95% confidence intervals are depicted by the black
line. All risk factors significantly associated with DSS in univariable analysis were included in the multivariable Cox regression analysis,
depicted by the grey lines
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several steps of this process, including promoting tumour cell
survival by acquisition of a malignant phenotype and increased
invasion in blood vessels.9
A recent meta-analysis has shown that high MVD was
associated with several poor prognostic variables, including deep
MI, positive LVSI and poor outcome in EC, although heterogeneity
due to differences in used antibodies and cut-off values hampers
interpretation of these results.23 Biologically, intratumoural
neoangiogenesis in response to hypoxia will promote the
formation of vasculature with high degrees of permeability and
potential for rapid growth.40 Our hypothesis that CAIX expression
with high degrees of vascular density would be associated with
unfavourable prognostic features and poor outcome was based
both on the facilitation of haematogenous spread in areas with
high angiogenesis and on the aggressive biological behaviour of
tumour cells after hypoxia.41,42 HIF-1α is stabilised and accumu-
lates under hypoxia, and activates transcription of numerous
genes involved in angiogenesis, proliferation and pH regulation
(VEGF, CAIX, glucose transporter-1).9 Our hypothesis was sup-
ported by the fact that ECs with positive CAIX expression and high
vascular density had a decreased DSS compared to ECs with only
one or none of both features. This observation supports the
complex interplay underlying the metastatic processes. The
observation that CAIX-positive ECs with high vascular density
did not have more lymph node metastasis or local recurrences,
but instead have more distant recurrences, could support the role
of angiogenesis in the haematogenous rather than the lympho-
genic metastatic process.
The obvious strengths of this study are the inclusion of a large
and representative cohort of EC patients within the ENITEC
network and the objective and reproducible measurement of
CAIX and MVD using digital imaging analyses. However, there
are some limitations that need to be addressed. Due to the
retrospective nature of the study, there were missing values,
specifically for LVSI and lymph node metastasis. Substantial LVSI
is a stronger predictor for prognosis of EC compared to
moderate LVSI. Also, LVSI is not routinely reported in the
pathologic report at all centres. Therefore, we assumed that if
substantial LVSI was present, it was reported, and if LVSI was not
reported, no substantial LVSI was present.31 Missing cases were
therefore coded as negative for LVSI. Separate analyses of
patients with available LVSI status did not alter the results of the
primary outcome (data not shown). Another general limitation
in interpretation of CAIX and MVD is the lack of standardised
criteria in the current literature, which hampers comparison of
previous studies and this study.29,30 However, the applied digital
Disease-free survival
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1.87 (0.99–3.55) p= 0.054
2.43 (1.37–4.31) p= 0.002
1.11 (0.56–2.20) p= 0.763
2.53 (1.03–6.25) p= 0.044
1.69 (0.81–3.52) p= 0.160
2.85 (1.24–6.58) p= 0.014
3.21 (1.72–6.00) p< 0.001
6.44 (3.26–12.71) p< 0.001
3.99 (2.22–7.16) p< 0.001
6.10 (3.26–11.4) p< 0.001
Fig. 4 Univariable and multivariable Cox regression analysis of clinicopathological parameters including carbonic anhydrase IX (CAIX)
combined with vascular density for disease-free survival (DFS). All risk factors significantly associated with DFS in univariable analysis were
included in the multivariable Cox regression analysis, depicted by the grey lines
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7.32 (3.26–16.45) p< 0.001
6.31 (3.11–12.80) p< 0.001
9.09 (4.40–18.74) p< 0.001
Fig. 5 Univariable and multivariable Cox regression analysis of clinicopathological parameters including carbonic anhydrase IX (CAIX)
combined with vascular density for distant disease-free survival (DDFS). All risk factors significantly associated with DDFS in univariable
analysis were included in the multivariable Cox regression analysis, depicted by the grey lines
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techniques in this study enable objective and reproducible
analyses without the need for extensive pathological expertise.
With the integration of digital pathology into clinical practice,
comparison of future studies with our results might be
easier.43,44 Although widely used to quantify MVD, CD34 is
known to also identify lymph vessels and stem cell populations,
which theoretically could have led to an overestimation of our
results. On the other hand, other antibodies, for example, CD31,
also carry the risk of aspecific staining. Compared to CD31,
CD34 staining is known to have stronger reactivity with
endothelial cells, resulting in a lower risk of staining failure.45
Finally, generalisability to non-endometrioid subtypes can be
questioned, as they comprise only 3.4% of the entire cohort.
More research focused on this specific subgroup could help to
strengthen these results.
This study identifies a group of patients with a poor DSS and
DDFS based on CAIX and MVD. Given the increased risk
of distant metastases, differential adjuvant treatment for these
ECs could be explored either in the form of chemotherapy or, in
the future, targeted therapies directed against angiogenesis.
Because of the focal character of CAIX expression in the tumour
tissue, performing the analysis on preoperative biopsies
might be challenging, but visualisation of hypoxia and
angiogenesis on FDG-PET/CT (fluorodeoxyglucose-positron
emission tomography/computed tomography) scan and mag-
netic resonance imaging could be an alternative, as Berg et al.5
showed recently.
In summary, we have found that CAIX expression and high
vascular density are prognostic markers for decreased survival in
EC. Combining these two markers revealed that ECs with positive
CAIX expression and high vascular density have an impaired
outcome compared to ECs that have only one or none of both
features. These patients experienced more distant recurrences,
and therefore differential adjuvant treatment for these tumours
should be explored.
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